UA74066C2 - Derivatives of 4,5-dihydro-1n-pyrazole with antagonistic activity relative to receptors of canabis-1, a method for the preparation trhereof, a pharmaceutical composition and a method for treatment - Google Patents

Derivatives of 4,5-dihydro-1n-pyrazole with antagonistic activity relative to receptors of canabis-1, a method for the preparation trhereof, a pharmaceutical composition and a method for treatment Download PDF

Info

Publication number: UA74066C2
Authority: UA; Ukraine
Prior art keywords: chlorophenyl; phenyl; dihydro; formula; pyrazole
Prior art date: 2001-03-22

Application number

UA2003109493A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-22

Filing date

2002-03-18

Publication date

2005-10-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8180044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA74066(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-18 Application filed filed Critical

2005-10-17 Publication of UA74066C2 publication Critical patent/UA74066C2/uk

Links

238000000034 method Methods 0.000 title claims description 10
239000008194 pharmaceutical composition Substances 0.000 title claims description 4
230000003042 antagnostic effect Effects 0.000 title description 3
238000002360 preparation method Methods 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims abstract description 52
125000000217 alkyl group Chemical group 0.000 claims abstract description 10
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 9
MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical class C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 claims abstract description 7
150000003839 salts Chemical class 0.000 claims abstract description 7
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 6
229910052736 halogen Inorganic materials 0.000 claims abstract description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 4
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
239000001257 hydrogen Substances 0.000 claims abstract description 4
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 4
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims abstract description 3
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims abstract description 3
229940002612 prodrug Drugs 0.000 claims abstract description 3
239000000651 prodrug Substances 0.000 claims abstract description 3
125000001424 substituent group Chemical group 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 14
229930003827 cannabinoid Natural products 0.000 claims description 10
239000003557 cannabinoid Substances 0.000 claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 6
208000035475 disorder Diseases 0.000 claims description 5
206010029216 Nervousness Diseases 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
230000005062 synaptic transmission Effects 0.000 claims description 4
208000020016 psychiatric disease Diseases 0.000 claims description 3
208000024827 Alzheimer disease Diseases 0.000 claims description 2
208000027559 Appetite disease Diseases 0.000 claims description 2
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
201000006474 Brain Ischemia Diseases 0.000 claims description 2
208000024172 Cardiovascular disease Diseases 0.000 claims description 2
206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
206010012289 Dementia Diseases 0.000 claims description 2
208000014094 Dystonic disease Diseases 0.000 claims description 2
208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
208000023105 Huntington disease Diseases 0.000 claims description 2
208000026139 Memory disease Diseases 0.000 claims description 2
208000002193 Pain Diseases 0.000 claims description 2
208000018737 Parkinson disease Diseases 0.000 claims description 2
208000028017 Psychotic disease Diseases 0.000 claims description 2
208000000323 Tourette Syndrome Diseases 0.000 claims description 2
208000016620 Tourette disease Diseases 0.000 claims description 2
208000015114 central nervous system disease Diseases 0.000 claims description 2
206010008118 cerebral infarction Diseases 0.000 claims description 2
201000010099 disease Diseases 0.000 claims description 2
208000010118 dystonia Diseases 0.000 claims description 2
206010015037 epilepsy Diseases 0.000 claims description 2
230000015654 memory Effects 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
208000008589 Obesity Diseases 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
235000020824 obesity Nutrition 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
239000005557 antagonist Substances 0.000 abstract description 13
125000005843 halogen group Chemical group 0.000 abstract description 5
241000218236 Cannabis Species 0.000 abstract 2
230000003389 potentiating effect Effects 0.000 abstract 2
102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
230000008018 melting Effects 0.000 description 30
238000002844 melting Methods 0.000 description 30
238000006243 chemical reaction Methods 0.000 description 19
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
102000005962 receptors Human genes 0.000 description 16
108020003175 receptors Proteins 0.000 description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
229960004132 diethyl ether Drugs 0.000 description 8
239000012071 phase Substances 0.000 description 8
239000002244 precipitate Substances 0.000 description 7
102000018208 Cannabinoid Receptor Human genes 0.000 description 6
108050007331 Cannabinoid receptor Proteins 0.000 description 6
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 6
230000005526 G1 to G0 transition Effects 0.000 description 6
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000000243 solution Substances 0.000 description 6
238000003756 stirring Methods 0.000 description 6
-1 for example Chemical group 0.000 description 5
SKLKZKAMWPQZLM-UHFFFAOYSA-N 3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1h-pyrazole Chemical compound C1=CC(Cl)=CC=C1C1=NNCC1C1=CC=CC=C1 SKLKZKAMWPQZLM-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
229940065144 cannabinoids Drugs 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
239000002253 acid Substances 0.000 description 3
239000000556 agonist Substances 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000003446 ligand Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000003208 petroleum Substances 0.000 description 3
239000003495 polar organic solvent Substances 0.000 description 3
238000010992 reflux Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
XPJPCDIVXGVHLY-UHFFFAOYSA-N 5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound N=1N(C(=N)N)CC(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 XPJPCDIVXGVHLY-UHFFFAOYSA-N 0.000 description 2
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
238000011161 development Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
240000004308 marijuana Species 0.000 description 2
230000003340 mental effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
OSNIIMCBVLBNGS-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)propan-1-one Chemical compound CN(C)C(C)C(=O)C1=CC=C2OCOC2=C1 OSNIIMCBVLBNGS-UHFFFAOYSA-N 0.000 description 1
FGCBXTLVUQGHQP-UHFFFAOYSA-N 3,4-dihydropyrazole-2-carboxamide Chemical class NC(=O)N1CCC=N1 FGCBXTLVUQGHQP-UHFFFAOYSA-N 0.000 description 1
GAZRNXIMWKZADY-UHFFFAOYSA-N 3,5-dimethylpyrazole-1-carboximidamide Chemical compound CC=1C=C(C)N(C(N)=N)N=1 GAZRNXIMWKZADY-UHFFFAOYSA-N 0.000 description 1
BFXHJFKKRGVUMU-UHFFFAOYSA-N 4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1 BFXHJFKKRGVUMU-UHFFFAOYSA-N 0.000 description 1
PMFKSNJVULPDBR-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-fluorophenyl)sulfonyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NC(=N)N1N=C(C=2C=CC(Cl)=CC=2)C(C=2C=CC=CC=2)C1 PMFKSNJVULPDBR-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
241000722948 Apocynum cannabinum Species 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
102100022404 E3 ubiquitin-protein ligase Midline-1 Human genes 0.000 description 1
101710102210 E3 ubiquitin-protein ligase Midline-1 Proteins 0.000 description 1
235000015928 Hibiscus cannabinus Nutrition 0.000 description 1
101100113585 Mus musculus Ccnb1ip1 gene Proteins 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000001593 cAMP accumulation Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
235000005607 chanvre indien Nutrition 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
150000001907 coumarones Chemical class 0.000 description 1
239000013078 crystal Substances 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000011534 incubation Methods 0.000 description 1
NONOKGVFTBWRLD-UHFFFAOYSA-N isocyanatosulfanylimino(oxo)methane Chemical class O=C=NSN=C=O NONOKGVFTBWRLD-UHFFFAOYSA-N 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
BQPIGGFYSBELGY-UHFFFAOYSA-N mercury(2+) Chemical class [Hg+2] BQPIGGFYSBELGY-UHFFFAOYSA-N 0.000 description 1
CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical class NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
238000000746 purification Methods 0.000 description 1
UCQFSGCWHRTMGG-UHFFFAOYSA-N pyrazole-1-carboximidamide Chemical compound NC(=N)N1C=CC=N1 UCQFSGCWHRTMGG-UHFFFAOYSA-N 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000011002 quantification Methods 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

UA2003109493A 2001-03-22 2002-03-18 Derivatives of 4,5-dihydro-1n-pyrazole with antagonistic activity relative to receptors of canabis-1, a method for the preparation trhereof, a pharmaceutical composition and a method for treatment UA74066C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01201062		2001-03-22
PCT/EP2002/003079 WO2002076949A1 (en)	2001-03-22	2002-03-18	4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity

Publications (1)

Publication Number	Publication Date
UA74066C2 true UA74066C2 (en)	2005-10-17

Family

ID=8180044

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2003109493A UA74066C2 (en)	2001-03-22	2002-03-18	Derivatives of 4,5-dihydro-1n-pyrazole with antagonistic activity relative to receptors of canabis-1, a method for the preparation trhereof, a pharmaceutical composition and a method for treatment

Country Status (25)

Country	Link
EP (1)	EP1373216B1 (de)
JP (1)	JP4373675B2 (de)
KR (1)	KR100846614B1 (de)
CN (1)	CN100366614C (de)
AR (1)	AR033046A1 (de)
AT (1)	ATE284872T1 (de)
AU (1)	AU2002256690B2 (de)
BR (1)	BR0205602A (de)
CA (1)	CA2422708C (de)
CZ (1)	CZ2003698A3 (de)
DE (1)	DE60202270T2 (de)
ES (1)	ES2229132T3 (de)
HU (1)	HUP0303148A3 (de)
IL (1)	IL153508A (de)
MX (1)	MXPA03003534A (de)
NO (1)	NO324953B1 (de)
NZ (1)	NZ524633A (de)
PL (1)	PL363751A1 (de)
PT (1)	PT1373216E (de)
RU (1)	RU2281941C2 (de)
SI (1)	SI1373216T1 (de)
SK (1)	SK287592B6 (de)
UA (1)	UA74066C2 (de)
WO (1)	WO2002076949A1 (de)
ZA (1)	ZA200307322B (de)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI231757B (en)	2001-09-21	2005-05-01	Solvay Pharm Bv	1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
NZ534757A (en)	2002-03-12	2006-07-28	Merck & Co Inc	Substituted amides
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
US7129239B2 (en)	2002-10-28	2006-10-31	Pfizer Inc.	Purine compounds and uses thereof
US7247628B2 (en)	2002-12-12	2007-07-24	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en)	2003-02-06	2008-02-12	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
US7176210B2 (en)	2003-02-10	2007-02-13	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7268133B2 (en)	2003-04-23	2007-09-11	Pfizer, Inc. Patent Department	Cannabinoid receptor ligands and uses thereof
US7141669B2 (en)	2003-04-23	2006-11-28	Pfizer Inc.	Cannabiniod receptor ligands and uses thereof
US7145012B2 (en)	2003-04-23	2006-12-05	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7232823B2 (en)	2003-06-09	2007-06-19	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
AR045533A1 (es) *	2003-09-02	2005-11-02	Solvay Pharm Gmbh	Uso de un compuesto antagonista de receptor de cb1, composicion farmaceutica y metodo de tratamiento y/o profilaxis de enfermedades relacionadas con dicho receptor de cb1
US7547693B2 (en)	2003-09-22	2009-06-16	Banyu Pharmaceutical Co. Ltd.	Piperidine derivative
TW200528102A (en) *	2003-10-24	2005-09-01	Solvay Pharm Gmbh	Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
EP1753413A2 (de) *	2003-10-24	2007-02-21	Solvay Pharmaceuticals GmbH	Neue medizinische anwendungen von verbindungen mit cb sb 1 /sb antagonistischer wirkung und kombinationsbehandlung mit diesen verbindungen
WO2005049615A1 (en) *	2003-11-21	2005-06-02	Pfizer Products Inc.	Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists
DE602005023124D1 (de)	2004-01-28	2010-10-07	Hoffmann La Roche	Spirobenzodioxole und deren verwendung als cb1-antagonisten
WO2005074920A1 (en) *	2004-01-30	2005-08-18	Solvay Pharmaceuticals B.V.	1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
US7649002B2 (en)	2004-02-04	2010-01-19	Pfizer Inc	(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
CN1938286A (zh)	2004-03-29	2007-03-28	默克公司	作为11－β－羟甾类脱氢酶－1抑制剂的二芳基三唑
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
US20060025448A1 (en)	2004-07-22	2006-02-02	Cadila Healthcare Limited	Hair growth stimulators
US7915252B2 (en)	2004-08-06	2011-03-29	Merck Sharp & Dohme	Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
CA2577060A1 (en)	2004-08-13	2006-02-23	Amgen Inc.	Substituted benzofused heterocycles
RU2007119315A (ru) *	2004-10-25	2008-11-27	Зольвай Фармасьютиклз Гмбх (De)	Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний
EP2286837A3 (de)	2004-11-01	2013-09-04	Amylin Pharmaceuticals, LLC	Behandlung von Fettleibigkeit und von verwandten Krankheiten
US8394765B2 (en)	2004-11-01	2013-03-12	Amylin Pharmaceuticals Llc	Methods of treating obesity with two different anti-obesity agents
RU2391337C2 (ru)	2004-11-09	2010-06-10	Ф.Хоффманн-Ля Рош Аг	Производные дибензосуберона
WO2006060186A2 (en) *	2004-11-30	2006-06-08	Bayer Pharmaceuticals Corporation	Pyrazole derivatives for the treatment of dementia and related disorders
WO2006060201A2 (en) *	2004-11-30	2006-06-08	Bayer Pharmaceuticals Corporation	Pyrazole derivatives for the treatment of psychiatric disorders
PA8660701A1 (es)	2005-02-04	2006-09-22	Pfizer Prod Inc	Agonistas de pyy y sus usos
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610580B8 (pt)	2005-05-30	2021-05-25	Banyu Pharma Co Ltd	composto derivado de piperidina
AU2006253842A1 (en)	2005-06-02	2006-12-07	Glenmark Pharmaceuticals S.A.	Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US7923465B2 (en)	2005-06-02	2011-04-12	Glenmark Pharmaceuticals S.A.	Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
EP1757587A1 (de) *	2005-07-15	2007-02-28	Laboratorios Del Dr. Esteve, S.A.	Substituierte Pyrazolinderivate, ihre Herstellung und Verwendung als Arzneimittel
EP1916239A4 (de)	2005-08-10	2009-10-21	Banyu Pharma Co Ltd	Pyridolverbindung
EP2330125A3 (de)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Hybridpolypeptide mit auswählbaren Eigenschaften
CA2617649A1 (en)	2005-08-11	2007-02-22	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
DE602006017712D1 (de)	2005-08-24	2010-12-02	Banyu Pharma Co Ltd	Phenylpyridonderivat
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
JPWO2007049798A1 (ja)	2005-10-27	2009-04-30	萬有製薬株式会社	新規ベンゾオキサチイン誘導体
AU2006312557B2 (en)	2005-11-10	2011-12-08	Msd K.K.	Aza-substituted spiro derivative
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
EP1801098A1 (de)	2005-12-16	2007-06-27	Merck Sante	2-Adamantylharnstoff Derivative als selektive 11B-HSD1 Inhibitoren
MEP6808A (xx)	2006-02-23	2010-02-10	Lundbeck & Co As H	Priperidinoilpirodolini agonisti receptora menalokortina tipa 4
AU2007245733A1 (en) *	2006-04-27	2007-11-08	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising CBX cannabinoid receptor modulators and Potassium channel modulators
US7763607B2 (en)	2006-04-27	2010-07-27	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
JP2010500300A (ja)	2006-08-08	2010-01-07	サノフィ−アベンティス	アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2083831B1 (de)	2006-09-22	2013-12-25	Merck Sharp & Dohme Corp.	Verfahren zur behandlung von fettsäure-synthese-hemmern
AU2007301126A1 (en)	2006-09-28	2008-04-03	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
EP2084127A1 (de)	2006-11-13	2009-08-05	Pfizer Products Inc.	Diaryl-, dipyridinyl- und arylpyridinylderivate und anwendungen davon
ATE547394T1 (de)	2006-12-01	2012-03-15	Bristol Myers Squibb Co	N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
EP1935420A1 (de)	2006-12-21	2008-06-25	Merck Sante	2-Adamantyl-Butyramid Derivate als selektive 11Beta-HSD1 Inhibitoren
US8106086B2 (en)	2007-04-02	2012-01-31	Msd K.K.	Indoledione derivative
AU2008261102B2 (en)	2007-06-04	2013-11-28	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN101318931B (zh) *	2007-06-04	2010-05-19	上海阳帆医药科技有限公司	二芳基取代吡唑衍生物、其制备方法和用途
US20100120694A1 (en)	2008-06-04	2010-05-13	Synergy Pharmaceuticals, Inc.	Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB2456183A (en) *	2008-01-04	2009-07-08	Gw Pharma Ltd	Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
WO2009110510A1 (ja)	2008-03-06	2009-09-11	萬有製薬株式会社	アルキルアミノピリジン誘導体
JPWO2009119726A1 (ja)	2008-03-28	2011-07-28	Ｍｓｄ株式会社	メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
EP2110374A1 (de)	2008-04-18	2009-10-21	Merck Sante	Benzofuran, Benzothiophen, Benzothiazolderivate als FXR-Modulatoren
JPWO2009154132A1 (ja)	2008-06-19	2011-12-01	Ｍｓｄ株式会社	スピロジアミン−ジアリールケトオキシム誘導体
WO2010003624A2 (en)	2008-07-09	2010-01-14	Sanofi-Aventis	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
ES2624828T3 (es)	2008-07-16	2017-07-17	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2010013595A1 (ja)	2008-07-30	2010-02-04	萬有製薬株式会社	５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
US8592403B2 (en)	2008-08-06	2013-11-26	Pfizer Limited	Diazepine and diazocane compounds as MC4 agonists
MX2011004258A (es)	2008-10-22	2011-06-01	Merck Sharp & Dohme	Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
MX2011004551A (es)	2008-10-30	2011-05-25	Merck Sharp & Dohme	Antagonistas del receptor de orexina de isonicotinamida.
JP5557845B2 (ja)	2008-10-31	2014-07-23	メルク・シャープ・アンド・ドーム・コーポレーション	糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
JP5514831B2 (ja)	2008-11-17	2014-06-04	メルク・シャープ・アンド・ドーム・コーポレーション	糖尿病の治療のための置換二環式アミン
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010075068A1 (en)	2008-12-16	2010-07-01	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (de)	2008-12-16	2011-10-26	Schering Corporation	Bicyclische pyranonderivate als agonisten am nicotinsäurerezeptor
WO2010079241A1 (es)	2009-01-12	2010-07-15	Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion	Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
WO2011011506A1 (en)	2009-07-23	2011-01-27	Schering Corporation	Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2768577A1 (en)	2009-07-23	2011-01-27	Schering Corporation	Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
RU2012111354A (ru)	2009-08-26	2013-10-10	Санофи	Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование
JP2013510834A (ja)	2009-11-16	2013-03-28	メリテク	［１，５］‐ジアゾシン誘導体
CA2784799C (en)	2009-12-30	2014-06-10	Shanghai Fochon Pharmaceutical Co Ltd	Certain dipeptidyl peptidase inhibtors
AR079935A1 (es) *	2010-01-29	2012-02-29	Abbott Healthcare Products Bv	Sintesis de derivados de pirazolin carboxamidina sustituida
CA2786314A1 (en)	2010-02-25	2011-09-01	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011137024A1 (en)	2010-04-26	2011-11-03	Merck Sharp & Dohme Corp.	Novel spiropiperidine prolylcarboxypeptidase inhibitors
WO2011143057A1 (en)	2010-05-11	2011-11-17	Merck Sharp & Dohme Corp.	Novel prolylcarboxypeptidase inhibitors
EP2579873A4 (de)	2010-06-11	2013-11-27	Merck Sharp & Dohme	Neuartige prolylcarboxypeptidase-hemmer
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
EP2677869B1 (de)	2011-02-25	2017-11-08	Merck Sharp & Dohme Corp.	Neue cyclische azabenzimidazolderivate als antidiabetika
WO2012120053A1 (de)	2011-03-08	2012-09-13	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683701B1 (de)	2011-03-08	2014-12-24	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de)	2011-03-08	2015-06-24	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de)	2011-03-08	2014-12-24	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de)	2011-03-08	2015-04-22	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US8680131B2 (en)	2012-07-25	2014-03-25	Jenrin Discovery, Inc.	Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
CA2880901A1 (en)	2012-08-02	2014-02-06	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
CA2889697C (en)	2012-11-13	2023-03-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Cannabinoid receptor mediating compounds
US11155521B2 (en)	2012-11-13	2021-10-26	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Cannabinoid receptor mediating compounds
MX2015010935A (es)	2013-02-22	2015-10-29	Merck Sharp & Dohme	Compuestos biciclicos antidiabeticos.
EP2970119B1 (de)	2013-03-14	2021-11-03	Merck Sharp & Dohme Corp.	Neuartige indolderivate als antidiabetika
HK1220611A1 (zh)	2013-03-15	2017-05-12	Bausch Health Ireland Limited	用於治疗胃肠道病症的组成物
US9708367B2 (en)	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
EP3004138B1 (de)	2013-06-05	2024-03-13	Bausch Health Ireland Limited	Ultrareine agonisten von guanylatcyclase c, verfahren zur herstellung und verwendung davon
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
AU2015255765A1 (en)	2014-05-09	2016-11-24	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Pyrazole derivatives and their use as cannabinoid receptor mediators
CA2959208C (en)	2014-08-29	2023-09-19	Tes Pharma S.R.L.	Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
WO2017151802A1 (en) *	2016-03-04	2017-09-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Cannabinoid receptor mediating compounds
CA3038185A1 (en)	2016-10-14	2018-04-19	Tes Pharma S.R.L.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en)	2016-12-06	2018-06-14	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
EP3883930A1 (de)	2018-11-20	2021-09-29	Tes Pharma S.r.l.	Inhibitoren der alpha-amino-beta-carboxymuconsäure-semialdehyddecarboxylase
EP3923933A4 (de)	2019-02-13	2022-08-17	Merck Sharp & Dohme Corp.	Pyrrolidinorexin-rezeptor-agonisten
EP3924058B1 (de)	2019-02-13	2026-01-07	Merck Sharp & Dohme LLC	5-alkyl-pyrrolidinorexinrezeptor-agonisten
US12312332B2 (en)	2019-08-08	2025-05-27	Merck Sharp & Dohme Llc	Heteroaryl pyrrolidine and piperidine orexin receptor agonists
US11680060B2 (en)	2020-08-18	2023-06-20	Merck Sharp & Dohme Llc	Bicycloheptane pyrrolidine orexin receptor agonists
WO2022245627A1 (en) *	2021-05-17	2022-11-24	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	A facile and odor-free approach to convert sulfonyl urea derivatives to chalcogenide sulfonyl urea derivatives
US20250248973A1 (en) *	2022-04-07	2025-08-07	Corbus Pharmaceuticals, Inc.	Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof
WO2025103493A1 (zh) *	2023-11-16	2025-05-22	西藏海思科制药有限公司	一种大麻素受体1拮抗剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL158178B (nl) *	1974-07-12	1978-10-16	Philips Nv	Werkwijze ter bereiding van insekticide preparaten die een pyrazolinederivaat bevatten, aldus verkregen gevormde preparaten, en werkwijze ter bereiding van pyrazolinederivaten met insekticide werking.
DE3431926A1 (de) *	1984-08-30	1986-03-06	Bayer Ag, 5090 Leverkusen	Amidinoazole
FR2692575B1 (fr) *	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) *	1993-12-02	1996-03-01	Sanofi Sa	N-pipéridino-3-pyrazolecarboxamide substitué.
RU2245878C2 (ru) *	2000-03-23	2005-02-10	Солвей Фармасьютикалс Б.В.	Производные 4,5-дигидро-1н-пиразола, обладающие cb1-антагонистической активностью
AR034160A1 (es) *	2000-09-30	2004-02-04	Gruenenthal Gmbh	Sulfonilguanidinas, medicamentos que contienen estos compuestos y el uso de sulfonilguanidinas

2002
- 2002-03-18 KR KR1020027018040A patent/KR100846614B1/ko not_active Expired - Fee Related
- 2002-03-18 EP EP02726190A patent/EP1373216B1/de not_active Expired - Lifetime
- 2002-03-18 RU RU2003105900/04A patent/RU2281941C2/ru not_active IP Right Cessation
- 2002-03-18 NZ NZ524633A patent/NZ524633A/en unknown
- 2002-03-18 CA CA2422708A patent/CA2422708C/en not_active Expired - Fee Related
- 2002-03-18 AT AT02726190T patent/ATE284872T1/de active
- 2002-03-18 JP JP2002576210A patent/JP4373675B2/ja not_active Expired - Fee Related
- 2002-03-18 IL IL153508A patent/IL153508A/en not_active IP Right Cessation
- 2002-03-18 CZ CZ2003698A patent/CZ2003698A3/cs unknown
- 2002-03-18 HU HU0303148A patent/HUP0303148A3/hu unknown
- 2002-03-18 MX MXPA03003534A patent/MXPA03003534A/es active IP Right Grant
- 2002-03-18 PL PL02363751A patent/PL363751A1/xx not_active IP Right Cessation
- 2002-03-18 SI SI200230065T patent/SI1373216T1/xx unknown
- 2002-03-18 UA UA2003109493A patent/UA74066C2/uk unknown
- 2002-03-18 ES ES02726190T patent/ES2229132T3/es not_active Expired - Lifetime
- 2002-03-18 AU AU2002256690A patent/AU2002256690B2/en not_active Ceased
- 2002-03-18 DE DE60202270T patent/DE60202270T2/de not_active Expired - Lifetime
- 2002-03-18 PT PT02726190T patent/PT1373216E/pt unknown
- 2002-03-18 SK SK308-2003A patent/SK287592B6/sk not_active IP Right Cessation
- 2002-03-18 AR ARP020100954A patent/AR033046A1/es unknown
- 2002-03-18 CN CNB028017773A patent/CN100366614C/zh not_active Expired - Fee Related
- 2002-03-18 WO PCT/EP2002/003079 patent/WO2002076949A1/en not_active Ceased
- 2002-03-18 BR BR0205602-0A patent/BR0205602A/pt not_active Application Discontinuation
2003
- 2003-06-23 NO NO20032892A patent/NO324953B1/no not_active IP Right Cessation
- 2003-09-18 ZA ZA200307322A patent/ZA200307322B/en unknown

Also Published As

Publication number	Publication date
AR033046A1 (es)	2003-12-03
NO20032892L (no)	2003-11-18
BR0205602A (pt)	2003-07-08
JP4373675B2 (ja)	2009-11-25
WO2002076949A1 (en)	2002-10-03
DE60202270T2 (de)	2005-05-19
KR100846614B1 (ko)	2008-07-16
NZ524633A (en)	2005-02-25
EP1373216A1 (de)	2004-01-02
HUP0303148A2 (hu)	2004-01-28
CZ2003698A3 (cs)	2003-06-18
NO324953B1 (no)	2008-01-14
CN100366614C (zh)	2008-02-06
CA2422708A1 (en)	2002-10-03
IL153508A0 (en)	2003-07-06
PL363751A1 (en)	2004-11-29
ES2229132T3 (es)	2005-04-16
ZA200307322B (en)	2004-12-20
CN1486301A (zh)	2004-03-31
IL153508A (en)	2008-07-08
SI1373216T1 (en)	2005-06-30
JP2004518763A (ja)	2004-06-24
KR20030082890A (ko)	2003-10-23
ATE284872T1 (de)	2005-01-15
MXPA03003534A (es)	2005-01-25
SK3082003A3 (en)	2003-10-07
DE60202270D1 (de)	2005-01-20
HUP0303148A3 (en)	2009-08-28
RU2281941C2 (ru)	2006-08-20
NO20032892D0 (no)	2003-06-23
AU2002256690B2 (en)	2006-05-18
EP1373216B1 (de)	2004-12-15
CA2422708C (en)	2010-10-26
SK287592B6 (sk)	2011-03-04
HK1061852A1 (zh)	2004-10-08
PT1373216E (pt)	2005-05-31

Publication	Publication Date	Title
UA74066C2 (en)	2005-10-17	Derivatives of 4,5-dihydro-1n-pyrazole with antagonistic activity relative to receptors of canabis-1, a method for the preparation trhereof, a pharmaceutical composition and a method for treatment
RU2286988C2 (ru)	2006-11-10	Производные 4,5-дигидро-1h-пиразола, обладающие сильной cb1-антагонистической активностью
RU2245878C2 (ru)	2005-02-10	Производные 4,5-дигидро-1н-пиразола, обладающие cb1-антагонистической активностью
HRP20040085A2 (en)	2004-08-31	Novel 4,5-dihydro-1h-pyrazole derivatives having cb-1 agonistic activity
UA77440C2 (en)	2006-12-15	1h-imidazole derivatives as potent cannabinoid-cb1 receptor agonists, partial agonists or antagonists, methods of their preparation (variants), intermediates, pharmaceutical composition and method for preparation thereof
TW200934497A (en)	2009-08-16	Heterocyclic derivatives
CN103073455B (zh)	2015-08-19	一类新型的kcnq钾通道激动剂、其制备方法和用途
TW200522964A (en)	2005-07-16	5-aryl-pyrimidine derivatives
JP2021500416A (ja)	2021-01-07	疼痛及び疼痛関連状態を治療するための新規アルコキシアミノ誘導体
ES2874628T3 (es)	2021-11-05	Compuestos de fluoropiperidina como antagonistas puros del receptor 5-HT6
IL298238A (en)	2023-01-01	An aniline compound used as a rory capsule
JP2022506378A (ja)	2022-01-17	疼痛及び疼痛に関連する状態を処置するための新規なテトラヒドロピリミドジアゼピン及びテトラヒドロピリドジアゼピン化合物
TH2101005032A (th)	2024-12-23	สารประกอบสารยับยั้ง jak และการใช้ประโยชน์ของสารนั้น
Cortes-Salva	2011	Guanidines, Amidines and Carbamides as Novel Sigma Receptor Ligands for Post-Stroke Therapeutics
BR112018007289B1 (pt)	2024-03-26	Compostos de derivado de oxadiazol amina como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
HK1061852B (en)	2008-07-18	4,5-dihydro-ih-pyrazole derivatives having cb1-antagonistic activity
HK1117512A (en)	2009-01-16	4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity